Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Taxes (2016 - 2025)

Historic Change in Taxes for Ani Pharmaceuticals (ANIP) over the last 12 years, with Q3 2025 value amounting to -$12.5 million.

  • Ani Pharmaceuticals' Change in Taxes fell 28764.29% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 5300.61%. This contributed to the annual value of -$1.4 million for FY2024, which is 11180.05% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Change in Taxes of -$12.5 million as of Q3 2025, which was down 28764.29% from -$10.9 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Change in Taxes ranged from a high of $12.9 million in Q4 2024 and a low of -$14.3 million during Q2 2024
  • Over the past 5 years, Ani Pharmaceuticals' median Change in Taxes value was -$247000.0 (recorded in 2021), while the average stood at -$692631.6.
  • Its Change in Taxes has fluctuated over the past 5 years, first skyrocketed by 1553877.55% in 2023, then crashed by 394220.96% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Change in Taxes stood at -$637000.0 in 2021, then skyrocketed by 92.31% to -$49000.0 in 2022, then surged by 15538.78% to $7.6 million in 2023, then soared by 69.9% to $12.9 million in 2024, then crashed by 197.63% to -$12.5 million in 2025.
  • Its last three reported values are -$12.5 million in Q3 2025, -$10.9 million for Q2 2025, and $7.4 million during Q1 2025.